Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
Phase of Trial: Phase III
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 14 Jun 2017 Status changed from active, no longer recruiting to completed.
- 04 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
- 01 Oct 2016 This trial is Completed in Austria, according to the European Clinical Trials Database.